FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.
2 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 2 separate news trends connected to Ivonescimab, spanning September 4, 2026 through November 15, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 14 article observations and 14 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.